causal

Manufacturing cost limits how many strains a drug can contain

The primary risk for microbial therapies is manufacturing: when production is expensive, developers must include fewer bacterial strains, which increases the risk of failing to capture the community that works, while cheaper manufacturing lets more strains be included.

causalpending

Speaker

Mark Smith

Evidence Quote

“Manufacturing is one of the key risks here... If manufacturing is really expensive, as it is today, you have to take more risks, because you can put fewer things into your product.”

Source

Finch Therapeutics: Empowering Immune Systems— Business Breakdowns
Created: 11/16/2026, 7:13:42 PM

Your notes

Loading notes...